{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:14:41Z","timestamp":1754162081218,"version":"3.41.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1023\/a:1020633300898","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T15:27:35Z","timestamp":1048001255000},"page":"383-387","source":"Crossref","is-referenced-by-count":2,"title":["Phase I Escalation of Gemcitabine Combined with Protracted Oral Etoposide in Gynecologic Malignancies \u2013 A Gynecologic Oncology Group Study"],"prefix":"10.1007","volume":"20","author":[{"given":"Agustin A.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine Y.","family":"Look","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5091990_CR1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","volume":"57","author":"G Omura","year":"1986","unstructured":"Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecology Oncology Group Study. Cancer 57:1725\u20131730, 1986","journal-title":"Cancer"},{"key":"5091990_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge E, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136, 1996","journal-title":"N Engl J Med"},{"key":"5091990_CR3","first-page":"356a","volume":"18","author":"RF Ozols","year":"1999","unstructured":"Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, Baergen R: Randomized phase III study of cisplatin (cis)\/paclitaxel (pac) versus carboplatin (carbo)\/pac in optimal stage III epithelial ovarian cancer (oc): a Gynecologic Oncology Group trial. Proc ASCO 18:356a, 1999 (abstract)","journal-title":"Proc ASCO"},{"key":"5091990_CR4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL: Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389\u2013393, 1991","journal-title":"J Clin Oncol"},{"key":"5091990_CR5","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","volume":"16","author":"MA Bookman","year":"1998","unstructured":"Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345\u20133352, 1998","journal-title":"J Clin Oncol"},{"key":"5091990_CR6","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","volume":"18","author":"AN Gordon","year":"2000","unstructured":"Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T: Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093\u20133100, 2000","journal-title":"J Clin Oncol"},{"key":"5091990_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR, Homesley HD: Prolonged oral etoposide as second line therapy for platinum\/paclitaxel-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405\u2013410, 1998","journal-title":"J Clin Oncol"},{"key":"5091990_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","volume":"63","author":"JD Shapiro","year":"1996","unstructured":"Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63:89\u201393, 1996","journal-title":"Gynecol Oncol"},{"key":"5091990_CR9","first-page":"368a","volume":"18","author":"JJ Kavanaugh","year":"1999","unstructured":"Kavanaugh JJ, Winn R, Steger M, Nelson-Taylor T, Edwards K, Rodgers R, Borst J, Kudelka AP, Hu W, Vershraegen CF: Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update. Proc ASCO 18:368a, 1999 (abstract)","journal-title":"Proc ASCO"},{"key":"5091990_CR10","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","volume":"34","author":"KR Hande","year":"1998","unstructured":"Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514\u20131521, 1998","journal-title":"Eur J Cancer"},{"key":"5091990_CR11","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2\u20322\u2032 difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110\u20136117, 1991","journal-title":"Cancer Res"},{"key":"5091990_CR12","first-page":"a2425","volume":"36","author":"H Nakamura","year":"1995","unstructured":"Nakamura H, Yamaji Y, Fujita J, Takahara J: Synergistic growth inhibition of gemcitabine\/cisplatin and gemcitabine\/etoposide on a human lung cancer cell line, RERF-LCOK. Proc AACR 36:a2425, 1995 (abstract)","journal-title":"Proc AACR"},{"key":"5091990_CR13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/bjc.1997.154","volume":"75","author":"PB Jensen","year":"1997","unstructured":"Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M: In vitro cross-resistance and collateral sensitivity in seven resistant small cell lung cancer cell lines: preclinical identification of suitable drug partner to taxotere, taxol, topotecan and gemcitabine. Brit J Cancer 75:869\u2013877, 1997","journal-title":"Brit J Cancer"},{"key":"5091990_CR14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-2952(98)00316-5","volume":"57","author":"CJA Van Moorsel","year":"1999","unstructured":"Van Moorsel CJA, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ: Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 57:407\u2013415, 1999","journal-title":"Biochem Pharmacol"},{"key":"5091990_CR15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/1097-0142(20000801)89:3<543::AID-CNCR9>3.0.CO;2-V","volume":"89","author":"TS Mok","year":"2000","unstructured":"Mok TS, Zee B, Chan AT, Yeo W, Yang WT, Yim A, Leung SF, Nguyen B, Leung TW, Johnson P: A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced non-small cell lung carcinoma. Cancer 89:543\u2013550, 2000","journal-title":"Cancer"},{"key":"5091990_CR16","first-page":"a207","volume":"17","author":"G Al-Jazayrly","year":"1998","unstructured":"Al-Jazayrly G, Gandara D, Tanaka M, Meyers F, Wun T, Drakes T, Edelman M, Richman E, Richman C, Sy M, Lara P, Lim N, Gummaraju S, Christensen S, Houston J, Lauder I, Lau D: Intrapatient dose escalation of gemcitabine and oral etoposide in advanced solid tumors. Proc ASCO 17:a207, 1998 (abstract)","journal-title":"Proc ASCO"},{"key":"5091990_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.1994.12.1.60","volume":"12","author":"PJ Hoskins","year":"1994","unstructured":"Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60\u201363, 1994","journal-title":"J Clin Oncol"},{"key":"5091990_CR18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/oxfordjournals.annonc.a058565","volume":"4","author":"M Marzola","year":"1993","unstructured":"Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani O, D'Incalci M, Cavalli F, Mangioni C: Low-dose oral etoposide in epithelial ovarian cancer of the ovary. Ann Oncol 4:517\u2013519, 1993","journal-title":"Ann Oncol"},{"key":"5091990_CR19","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1007\/BF00684867","volume":"34","author":"SP Joel","year":"1994","unstructured":"Joel SP, Shah R, Slevin ML: Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 34:S69\u2013S75, 1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"5091990_CR20","first-page":"2566","volume":"46","author":"M D'Incalci","year":"1986","unstructured":"D'Incalci M, Rossi C, Zucchetti M, Urso R, Cavalli F, Mangioni C, Willems Y, Sessa C: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46:2566\u20132571, 1986","journal-title":"Cancer Res"},{"key":"5091990_CR21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF00686147","volume":"31","author":"KH Pfluger","year":"1993","unstructured":"Pfluger KH, Hahn M, Holz JB, Schmidt L, Kohl P, Fritsch HW, Jungclas H, Havemann K: Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 31: 350\u2013356, 1993","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020633300898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1020633300898\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020633300898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:59:27Z","timestamp":1753819167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1020633300898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["5091990"],"URL":"https:\/\/doi.org\/10.1023\/a:1020633300898","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}